Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Oral glycoprotein IIb/IIIa inhibitors may enhance early treatment benefits for acute coronary syndromes.
• Investigating novel oral agents is crucial for preventing subsequent cardiac events.

Purpose of the Study:

• To assess the safety and preliminary efficacy of lefradafiban, an oral GP IIb/IIIa blocker.
• To evaluate three dose levels of lefradafiban in patients with unstable angina or myocardial infarction.

Main Methods:

• A dose-escalation trial (FROST) randomized 531 patients to lefradafiban (20, 30, 45 mg t.i.d.) or placebo.
• Efficacy assessed by cardiac events (death, MI, revascularization, angina); safety by bleeding (TIMI criteria) and lab parameters.

Main Results:

• A trend towards reduced cardiac events was observed with lefradafiban 30 mg, particularly in patients with elevated baseline troponin I.
• A dose-dependent increase in bleeding events occurred, with excessive risk at 45 mg, leading to discontinuation.
• Increased neutropenia was noted in lefradafiban groups, attributed to neutrophil redistribution.

Conclusions:

• One-month lefradafiban treatment showed a decrease in cardiac events at 30 mg and a dose-dependent rise in hemorrhage.
• The favorable trend in elevated troponin patients warrants confirmation in larger clinical trials.